Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 481Neoplasms 294Breast Neoplasms 282Colorectal Neoplasms 225Neoplasm Metastasis 191Prostatic Neoplasms 172Ovarian Neoplasms 165Lung Neoplasms 155Multiple Myeloma 153Recurrence 133Melanoma 117Pancreatic Neoplasms 114Squamous Cell Carcinoma of Head and Neck 105Stomach Neoplasms 98Endometrial Neoplasms 98Leukemia, Myeloid, Acute 96Small Cell Lung Carcinoma 85Leukemia, Lymphocytic, Chronic, B-Cell 83Lymphoma, Non-Hodgkin 82Triple Negative Breast Neoplasms 81Carcinoma, Renal Cell 81Carcinoma, Hepatocellular 80Urinary Bladder Neoplasms 75Lymphoma, Large B-Cell, Diffuse 73Lymphoma, Follicular 67Advanced Solid Tumors 64Lymphoma 62Glioblastoma 60Parkinson Disease 4, Autosomal Dominant Lewy Body 56Head and Neck Neoplasms 54

Interventions

enzalutamide 1darolutamide 1cabazitaxel 1apalutamide 1Prednisone 1Docetaxel 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Metastatic Castration-resistant Prostate Neoplasms × 90 days × Clear all
NCT05818683 2026-06-05

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Janssen Research & Development, LLC

Phase 1 Recruiting
300 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

NCT07164443 2026-06-05

KLK2-comPAS

Janssen Research & Development, LLC

Phase 3 Recruiting
663 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡